Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Fortis Update:...

    Fortis Update: Munjals, Burmans better their offer, BLK promoter likely to bid

    Written by Ruby Khatun Khatun Published On 2018-04-19T18:16:15+05:30  |  Updated On 19 April 2018 6:16 PM IST
    Fortis Update: Munjals, Burmans better their offer, BLK promoter likely to bid

    New Delhi: Fortis Healthcare said it has received an improved binding offer from Hero Enterprise Investment Office and Burman Family Office to invest Rs 1,500 crore directly in the company, ahead of its scheduled board meet today.


    "The company has received an improved binding offer from Hero/Munjals and Burmans to invest directly into the company," Fortis Healthcare said in a regulatory filing.


    Spelling out the details of their offer, the Munjals and Burmans in a joint letter said, the offer is "faster to implement and without any due diligence. We are proposing to invest Rs 1,500 crore directly in the company".


    The Munjals and Burmans have offered to invest Rs 500 crore through preference issue of equity shares and Rs 1,000 crore through preferential issue of warrants, based on the current business and financial position of the company.


    Meanwhile, in a late-night filing yesterday, Fortis said it has also received a supplemental proposal from Malaysia's IHH Healthcare Bhd.


    "As part of the IHH proposal and subject to satisfactory completion of due diligence..We are ready to infuse Rs 4,000 crore through a preferential allotment of equity shares at a price not exceeding Rs 160 per share which will fund the buyout of RHT Health Trust assets as well as provide immediate liquidity towards working capital and infrastructure upgrades," IHH said.


    "Notwithstanding the foregoing, IHH remains flexible to jointly working with the existing shareholders of the company towards solving the company's funding requirements," it added.


    Munjals and Burmans have offered to invest Rs 750 crore upfront.


    Group entities of Hero Enterprise Investment Office led by Sunil Kant Munjal and the Burman family of the Dabur Group currently hold around 3 percent stake in the healthcare chain.


    Last week, Fortis had an "unsolicited binding offer" from Hero Enterprise Investment Office and Burman Family Office to invest Rs 1,250 crore in the company through preferential allotment route.


    As per the improved offer letter, allotment and pricing for the preferential issue of equity shares for Rs 500 crore shall be as per Sebi ICDR guidelines or Rs 156 per share, which is higher.


    Allotment and pricing for the preferential issue of warrants for Rs 1,000 crore shall be as per Sebi ICDR guidelines or Rs 161.60 per share, which is higher, it added.


    The board of directors of the company is scheduled to meet today to consider all the options.


    The offer letter stated that utilization of proceeds from the preferential issue of equity shares for Rs 500 crore shall only be for the purpose of payment of employee dues, repayment of loans which have matured and payment to the most pressing creditors and lenders.


    "We seek two board seats, given the sizeable investment, and to generally act in the interest of stakeholders," it added.


    IHH Healthcare Bhd, Manipal Health Enterprises Pvt Ltd, Burmans and Munjals (jointly) and Chinese firm Fosun Health Holdings are in the race for buying Fortis.


    IHH offered a price of 160 per share which valued the company at Rs 6,061 crore.


    The Malaysian firm's offer had come a day after Sunil Kant Munjal-led Hero Enterprise Investment Office and Burman Family Office offered to invest Rs 1,250 crore in the healthcare chain at up to Rs 156 per share.


    Fortis has also received an unsolicited non-binding expression of interest from Fosun Health Holdings Ltd, an arm of Fosun International Ltd, with a proposal of primary infusion at a price up to Rs 156 per share up to a total investment of USD 350 million (over Rs 2,295 crore).


    Manipal had raised its offer for Fortis last week to Rs 155 per share by valuing the hospital business higher at Rs 6,061 crore, from Rs 5,003 crore initially.


    A recent news in ET stated that owner of BLK hospital and KKR backed Radiant Hospitals will likely to bid to infuse cash in Fortis by offering to buy few assets housed under Singapore based RHT Trust.


    “We would not like to consider anything hostile to the intentions of the incumbent management or board. But we could explore (the assets) if a formal process is initiated”, Soi had told ET last week.


    A source closely involved in the deal told ET, "Radiant will make an offer to infuse cash around Rs 500 crore in Fortis and buy few hospital assets."
    binding offerBurman Family OfficeDabur Groupequity sharesFortisFortis HealthcareFosun Health HoldingsHero Enterprise Investment OfficeICDR guidelinesIHH HealthcareManipal Health EnterprisesRadiant HospitalsSEBISunil Kant Munjal
    Source : With Agency Inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok